URG4 expression in invasive breast carcinoma and its relation to clinicopathological characteristics
- 83 Downloads
Upregulated gene 4 (URG4) is a recently described oncogene that upregulates cell proliferation. Its overexpression has been identified in many malignancies, and it is thought to be related to tumour progression, angiogenesis, metastasis and the recurrence of many cancers. This is the first study to show its expression in breast cancer patients and its association with clinicopathological characteristics in these patients.
Fifty invasive ductal breast carcinoma cases and 25 control cases were included in the study. Tumourous tissues and control tissues were assessed molecularly for quantification of mRNA expression of URG4 and immunohistochemically for protein expression of URG4.
The mean ages of the patients and controls were 54.3 ± 11.3 and 38.9 ± 9.7 years, respectively. The expression levels of URG4 mRNA in tumour tissues were higher compared to control breast tissues (p = 0.023). An immunohistochemical assessment suggested that URG4 is strongly expressed in normal breast tissues and lower-grade (grades I and II) ductal carcinomas of the breast, but it is weakly expressed in high-grade (grade III) ductal breast carcinomas. Additionally, the immunohistochemical and molecular expression results of URG4 were relevant to most prognostic parameters (tumour size, oestrogen and progesterone receptor status, HER2 status and Ki67 proliferative index) for breast cancer. However, unlike the immunohistochemical studies, the molecular studies revealed that there was no significant difference in URG4 expression for different grades of tumour tissues.
The literature data suggest that URG4 overexpression is associated with poor prognosis in many types of cancer. Conversely, our results in breast cancer specimens indicate that URG4 overexpression in breast ductal carcinomas is significantly associated with good prognostic parameters. Nevertheless, these preliminary findings should be confirmed by further studies.
KeywordsURG4/URGCP Breast cancer mRNA expression Protein expression
This study was funded by Balıkesir University Coordinator of Scientific Research Projects. The authors would like to appreciate the help from Prof. Dr. Feray Koçkar and Dr. Esra Tokay, for their guidance on the processes in this study.
- 4.Wu M, Chen J, Wang Y, Hu J, Liu C, Feng C, et al. URGCP/URG4 promotes apoptotic resistance in bladder cancer cells by activating NF-κB signalling. Oncotarget. 2015;6:30887–901.Google Scholar
- 6.Cai J, Li R, Xu X, Zhang L, Wu S, Yang T, et al. URGCP promotes non-small cell lung cancer invasiveness by activating the NF-κB-MMP-9 pathway. Oncotarget. 2015;6:36489–504.Google Scholar
- 8.Dodurga Y, Gundogdu G, Koc T, Yonguç GN, Kucukatay V, Satıroğlu-Tufan NL, et al. Expression of URG4/URGCP, Cyclin D1, Bcl-2, and Bax genes in retinoic acid treated SH-SY5Y human neuroblastoma cells. Contemp Oncol (Pozn). 2013;17:346–9.Google Scholar
- 10.Dodurga Y, Oymak Y, Gündüz C, Satıroğlu-Tufan NL, Vergin C, Çetingül N, et al. Leukemogenesis as a new approach to investigate the correlation between up regulated gene 4/upregulator of cell proliferation (URG4/URGCP) and signal transduction genes in leukemia. Mol Biol Rep. 2013;40:3043–8.CrossRefGoogle Scholar
- 16.Likhite VS, Stossi F, Kim K, Katzenellenbogen BS, Katzenellenbogen JA. Kinase-specific phosphorylation of the estrogen receptor changes receptor interactions with ligand, deoxyribonucleic acid, and coregulators associated with alterations in estrogen and tamoxifen activity. Mol Endocrinol. 2006;20:3120–32.CrossRefGoogle Scholar